These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26375464)

  • 1. The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy).
    Angel JB; Routy JP; Graziani GM; Tremblay CL
    J Acquir Immune Defic Syndr; 2015 Oct; 70(2):122-8. PubMed ID: 26375464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune.
    Angel JB; Routy JP; Tremblay C; Ayers D; Woods R; Singer J; Bernard N; Kovacs C; Smaill F; Gurunathan S; Sekaly RP
    AIDS; 2011 Mar; 25(6):731-9. PubMed ID: 21330911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
    Autran B; Murphy RL; Costagliola D; Tubiana R; Clotet B; Gatell J; Staszewski S; Wincker N; Assoumou L; El-Habib R; Calvez V; Walker B; Katlama C;
    AIDS; 2008 Jul; 22(11):1313-22. PubMed ID: 18580611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.
    Leth S; Schleimann MH; Nissen SK; Højen JF; Olesen R; Graversen ME; Jørgensen S; Kjær AS; Denton PW; Mørk A; Sommerfelt MA; Krogsgaard K; Østergaard L; Rasmussen TA; Tolstrup M; Søgaard OS
    Lancet HIV; 2016 Oct; 3(10):e463-72. PubMed ID: 27658863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.
    Achenbach CJ; Assoumou L; Deeks SG; Wilkin TJ; Berzins B; Casazza JP; Lambert-Niclot S; Koup RA; Costagliola D; Calvez V; Katlama C; Autran B; Murphy RL;
    Lancet HIV; 2015 Mar; 2(3):e82-91. PubMed ID: 26424549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs.
    Turner JL; Kostman JR; Aquino A; Wright D; Szabo S; Bidwell R; Goodgame J; Daigle A; Kelley E; Jensen F; Duffy C; Carlo D; Moss RB
    HIV Med; 2001 Apr; 2(2):68-77. PubMed ID: 11737381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy.
    Sukeepaisarncharoen W; Churdboonchart V; Kulpradist S; Isarangkura Na Ayudthya B; Rugpao S; Chandeying V; Sirawaraporn W; Carlo D; Moss RB
    HIV Clin Trials; 2001; 2(5):391-8. PubMed ID: 11673813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand.
    Chantratita W; Sukeepaisarncharoen W; Chandeying V; Kulpradist S; Israngkura Na Ayudhtaya B; Rugpao S; Sirawaraporn W; Boonshuyar C; Churdboonchart V
    HIV Med; 2004 Sep; 5(5):317-25. PubMed ID: 15369506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy.
    Costiniuk CT; Kovacs C; Routy JP; Singer J; Gurunathan S; Sekaly RP; Angel JB
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):266-9. PubMed ID: 22908887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients.
    Castro P; Plana M; González R; López A; Vilella A; Argelich R; Gallart T; Pumarola T; Bayas JM; Gatell JM; García F
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1249-59. PubMed ID: 19943787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
    Churdboonchart V; Sakondhavat C; Kulpradist S; Na Ayudthya BI; Chandeying V; Rugpao S; Boonshuyar C; Sukeepaisarncharoen W; Sirawaraporn W; Carlo DJ; Moss R
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):728-33. PubMed ID: 10973445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
    Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
    J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.
    Kinloch-de Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A; Tambussi G; Girard PM; Bloch M; Battegay M; Carter N; El Habib R; Theofan G; Cooper DA; Perrin L;
    J Infect Dis; 2005 Aug; 192(4):607-17. PubMed ID: 16028129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir.
    Persaud D; Luzuriaga K; Ziemniak C; Muresan P; Greenough T; Fenton T; Blackford A; Ferguson K; Neu N; Cunningham CK
    AIDS; 2011 Nov; 25(18):2227-34. PubMed ID: 21918423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.
    de Jong W; Aerts J; Allard S; Brander C; Buyze J; Florence E; van Gorp E; Vanham G; Leal L; Mothe B; Thielemans K; Plana M; Garcia F; Gruters R;
    Trials; 2019 Jun; 20(1):361. PubMed ID: 31208472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
    Jacobson JM; Pat Bucy R; Spritzler J; Saag MS; Eron JJ; Coombs RW; Wang R; Fox L; Johnson VA; Cu-Uvin S; Cohn SE; Mildvan D; O'Neill D; Janik J; Purdue L; O'Connor DK; Vita CD; Frank I;
    J Infect Dis; 2006 Sep; 194(5):623-32. PubMed ID: 16897661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study.
    Goh LE; Perrin L; Hoen B; Cooper D; Phillips A; Janossy G; Sonnenborg A; Tsoukas C; Lampe F; Kinloch S;
    HIV Clin Trials; 2001; 2(5):438-44. PubMed ID: 11673819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
    Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
    Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.